Investors

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

NASDAQ: SNDX
$ 9.45 +0.18 (1.94%)
Day High: 9.79
Day Low:  9.22
Volume:    199,521
4:00 PM ET
02.21.18

Delayed ~20 min., by eSignal.

Press Releases


Events & Presentations